Journal of Cardiac Failure
Volume 16, Issue 9 , Pages 714-719, September 2010

The Effects of Adenosine A1 Receptor Antagonism in Patients With Acute Decompensated Heart Failure and Worsening Renal Function: The REACH UP Study

  • Stephen S. Gottlieb, MD

      Affiliations

    • University of Maryland, Baltimore, MD
    • Corresponding Author InformationReprint requests: Stephen Gottlieb, MD, University of Maryland School of Medicine, 22 S. Greene St, Baltimore, MD 21209. Tel: (410) 328-8788; Fax: (410) 328-1048.
    • ,
  • Michael M. Givertz, MD

      Affiliations

    • Brigham and Women's Hospital, Boston, MA
    • ,
  • Marco Metra, MD

      Affiliations

    • University of Brescia, Brescia, Italy
    • ,
  • Kevin Gergich, MA

      Affiliations

    • Merck & Co., Inc, Whitehouse Station, NJ
    • ,
  • Steven Bird, MS

      Affiliations

    • Merck & Co., Inc, Whitehouse Station, NJ
    • ,
  • Charlotte Jones-Burton, MD, MS

      Affiliations

    • Merck & Co., Inc, Whitehouse Station, NJ
    • ,
  • Barry Massie, MD

      Affiliations

    • University of California, San Francisco
    • ,
  • Gad Cotter, MD

      Affiliations

    • Momentum Research, Durham, NC
    • ,
  • Piotr Ponikowski, MD

      Affiliations

    • Military Hospital, Department of Health Sciences, Medical University, Wroclaw, Poland
    • ,
  • Beth Weatherley, PhD

      Affiliations

    • Momentum Research, Durham, NC
    • ,
  • Christopher O'Connor, MD

      Affiliations

    • Duke University Medical Center, Durham, NC
    • ,
  • Howard Dittrich, MD

      Affiliations

    • NovaCardia, Inc, San Diego, CA

Received 11 February 2010; received in revised form 16 April 2010; accepted 21 April 2010. published online 07 June 2010.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Funded by NovaCardia, Inc. As of September 2007, NovaCardia is a wholly owned subsidiary of Merck & Co, Inc. Based on the lack of a benefit on the predefined end points in the PROTECT trial, Merck has reported it will not pursue further development of rolofylline.

 All decisions regarding this manuscript were made by a guest editor.

 See page 719 for disclosure information.

PII: S1071-9164(10)00196-X

doi:10.1016/j.cardfail.2010.04.006

Journal of Cardiac Failure
Volume 16, Issue 9 , Pages 714-719, September 2010

Article Tools

* Image Usage & Resolution